For the pharma sector, the proposal includes cutting GST on rare disease drugs to nil from 5% and waiving GST entirely on over 30 cancer drugs, currently taxed at 12%.
For the pharma sector, the proposal includes cutting GST on rare disease drugs to nil from 5% and waiving GST entirely on over 30 cancer drugs, currently taxed at 12%.